Roivant announced a new Phase 2b/3 clinical program for brepocitinib in lichen planopilaris, a highly morbid inflammatory scalp disorder affecting approximately 100,000 adults in the United States.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ROIV:
- Bernstein bullish on Roivant Sciences, initiates with an Outperform
- Roivant Sciences initiated with an Outperform at Bernstein
- Roivant Sciences price target raised to $33 from $31 at JPMorgan
- Midday Fly By: Stocks climb as oil prices pull back
- Video: Moderna advances as settlement seen removing share overhang